Regal Assets Analytics

WDLangbein

About Bill Langbein

Before starting SanaCurrents, William (Bill) Langbein spent more than 20 years as a life science business journalist, with stops at California Medicine, In Vivo and Reuters Health. During that time, he wrote on genomic discoveries, the transition of the pharmaceutical companies to rely more on biologics, and the dawn of precision medicine, through which most drug developers came to recognize a one-drug-for-all approach would no longer work. One constant truth he learned is smaller companies deliver the most innovation and highest value to patients and investors. Yet because of the inherent volatility of biopharma and medical devices, small companies typically fly under the radar of investors. The emergence of precision medicine, however, reduces the volatility of small cap companies and increases the potential for strong returns. SanaCurrents was founded to identify the undervalued therapies that would benefit patients and investors the most.

SanaCurrents closing out Adverum Biotechnologies (ADVM)

By |2020-11-21T11:33:39-05:00November 17th, 2020|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Updates|Tags: |

Adverum Biotechnologies (NASDAQ:ADVM) on Saturday reported positive results from its [...]

SanaCurrents Pivotal Sentiment on Protagonist (PTGX) polycythemia vera phase II trial

By |2020-11-17T10:15:51-05:00November 14th, 2020|Categories: Bill Langbein, SanaCurrents, SanaCurrents Probability Sentiment|Tags: |

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Probability Sentiment [...]

Adverum catalyst set for Saturday, November 14

By |2020-11-17T10:16:00-05:00November 11th, 2020|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Updates|Tags: |

Adverum Biotechnologies (NASDAQ:ADVM) said it will present additional clinical data [...]

Calliditas’ Shares Soar About 35% After Hitting Catalyst

By |2020-11-09T12:00:46-05:00November 9th, 2020|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Updates|Tags: |

Sweden-based Calliditas Therapeutics’ (NASDAQ:CALT) delivered on its phase III trial [...]

SanaCurrents Advantageous Sentiment on Alimera Sciences, Inc. (ALIM) Revenue Growth

By |2020-11-09T09:33:07-05:00November 7th, 2020|Categories: Bill Langbein, SanaCurrents, SanaCurrents Probability Sentiment|Tags: |

Alimera Sciences, Inc. (NASDAQ:ALIM) Probability Sentiment [...]

FDA Places Partial Clinical Hold on Molecular Templates Trial; SanaCurrents Suspending Coverage

By |2020-11-06T10:39:56-05:00November 6th, 2020|Categories: Bill Langbein, SanaCurrents, SanaCurrents Updates|Tags: |

In an earnings release after the market closed on November [...]

Annexon, Inc. (ANNX) Probability Sentiment

By |2020-10-31T17:19:12-04:00October 31st, 2020|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents, SanaCurrents Probability Sentiment|Tags: |

$ANNX Probability Sentiment FEATURED CATALYST [...]